ASCENDIS PHARMA A/S - ADR (ASND) Fundamental Analysis & Valuation

NASDAQ:ASND • US04351P1012

Current stock price

225.98 USD
-3.03 (-1.32%)
At close:
225.98 USD
0 (0%)
After Hours:

This ASND fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. ASND Profitability Analysis

1.1 Basic Checks

  • ASND had negative earnings in the past year.
  • In the past year ASND had a positive cash flow from operations.
  • ASND had negative earnings in each of the past 5 years.
  • ASND had negative operating cash flow in 4 of the past 5 years.
ASND Yearly Net Income VS EBIT VS OCF VS FCFASND Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200M -400M

1.2 Ratios

  • With a decent Return On Assets value of -17.51%, ASND is doing good in the industry, outperforming 77.80% of the companies in the same industry.
Industry RankSector Rank
ROA -17.51%
ROE N/A
ROIC N/A
ROA(3y)-35.96%
ROA(5y)-39.35%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ASND Yearly ROA, ROE, ROICASND Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200 -200

1.3 Margins

  • The Gross Margin of ASND (86.82%) is better than 89.00% of its industry peers.
  • In the last couple of years the Gross Margin of ASND has grown nicely.
  • ASND does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 86.82%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.4%
GM growth 5YN/A
ASND Yearly Profit, Operating, Gross MarginsASND Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -2K -4K -6K -8K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. ASND Health Analysis

2.1 Basic Checks

  • ASND does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • ASND has more shares outstanding than it did 1 year ago.
  • ASND has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, ASND has an improved debt to assets ratio.
ASND Yearly Shares OutstandingASND Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
ASND Yearly Total Debt VS Total AssetsASND Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

2.2 Solvency

  • ASND has an Altman-Z score of 2.24. This is not the best score and indicates that ASND is in the grey zone with still only limited risk for bankruptcy at the moment.
  • ASND has a better Altman-Z score (2.24) than 65.64% of its industry peers.
  • The Debt to FCF ratio of ASND is 19.20, which is on the high side as it means it would take ASND, 19.20 years of fcf income to pay off all of its debts.
  • With an excellent Debt to FCF ratio value of 19.20, ASND belongs to the best of the industry, outperforming 90.15% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 19.2
Altman-Z 2.24
ROIC/WACCN/A
WACC7.05%
ASND Yearly LT Debt VS Equity VS FCFASND Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M -400M 600M 800M

2.3 Liquidity

  • ASND has a Current Ratio of 1.04. This is a normal value and indicates that ASND is financially healthy and should not expect problems in meeting its short term obligations.
  • The Current ratio of ASND (1.04) is worse than 86.10% of its industry peers.
  • A Quick Ratio of 0.76 indicates that ASND may have some problems paying its short term obligations.
  • ASND has a worse Quick ratio (0.76) than 88.03% of its industry peers.
Industry RankSector Rank
Current Ratio 1.04
Quick Ratio 0.76
ASND Yearly Current Assets VS Current LiabilitesASND Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. ASND Growth Analysis

3.1 Past

  • ASND shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 42.62%, which is quite impressive.
  • The Revenue has grown by 98.03% in the past year. This is a very strong growth!
  • ASND shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 152.98% yearly.
EPS 1Y (TTM)42.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.06%
Revenue 1Y (TTM)98.03%
Revenue growth 3Y141.43%
Revenue growth 5Y152.98%
Sales Q2Q%42.31%

3.2 Future

  • ASND is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 54.92% yearly.
  • ASND is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 36.05% yearly.
EPS Next Y227.33%
EPS Next 2Y122.09%
EPS Next 3Y85.22%
EPS Next 5Y54.92%
Revenue Next Year95.52%
Revenue Next 2Y67.28%
Revenue Next 3Y51.26%
Revenue Next 5Y36.05%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ASND Yearly Revenue VS EstimatesASND Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 1B 2B 3B
ASND Yearly EPS VS EstimatesASND Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 10 -10 20

More info and screens

Find the best growth stocksShow best growing peers

4

4. ASND Valuation Analysis

4.1 Price/Earnings Ratio

  • ASND reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Based on the Price/Forward Earnings ratio of 41.02, the valuation of ASND can be described as expensive.
  • 91.12% of the companies in the same industry are more expensive than ASND, based on the Price/Forward Earnings ratio.
  • When comparing the Price/Forward Earnings ratio of ASND to the average of the S&P500 Index (23.84), we can say ASND is valued expensively.
Industry RankSector Rank
PE N/A
Fwd PE 41.02
ASND Price Earnings VS Forward Price EarningsASND Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40 60

4.2 Price Multiples

  • Based on the Price/Free Cash Flow ratio, ASND is valued cheaply inside the industry as 90.93% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 262.31
EV/EBITDA N/A
ASND Per share dataASND EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • ASND's earnings are expected to grow with 85.22% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y122.09%
EPS Next 3Y85.22%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ASND Dividend Analysis

5.1 Amount

  • No dividends for ASND!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ASND Fundamentals: All Metrics, Ratios and Statistics

ASCENDIS PHARMA A/S - ADR

NASDAQ:ASND (3/13/2026, 8:10:25 PM)

After market: 225.98 0 (0%)

225.98

-3.03 (-1.32%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-11
Earnings (Next)04-29
Inst Owners104.92%
Inst Owner Change-0.43%
Ins Owners0.82%
Ins Owner ChangeN/A
Market Cap13.67B
Revenue(TTM)720.13M
Net Income(TTM)-228.03M
Analysts88.33
Price Target289.23 (27.99%)
Short Float %6.48%
Short Ratio5.31
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-721.94%
Min EPS beat(2)-1098.26%
Max EPS beat(2)-345.63%
EPS beat(4)1
Avg EPS beat(4)-349.46%
Min EPS beat(4)-1098.26%
Max EPS beat(4)49.75%
EPS beat(8)3
Avg EPS beat(8)-180.72%
EPS beat(12)6
Avg EPS beat(12)-116.14%
EPS beat(16)7
Avg EPS beat(16)-89.38%
Revenue beat(2)0
Avg Revenue beat(2)-1.76%
Min Revenue beat(2)-2.04%
Max Revenue beat(2)-1.48%
Revenue beat(4)2
Avg Revenue beat(4)2.63%
Min Revenue beat(4)-2.04%
Max Revenue beat(4)9.46%
Revenue beat(8)4
Avg Revenue beat(8)-2.24%
Revenue beat(12)7
Avg Revenue beat(12)14.27%
Revenue beat(16)11
Avg Revenue beat(16)18.77%
PT rev (1m)4.1%
PT rev (3m)8.62%
EPS NQ rev (1m)6.38%
EPS NQ rev (3m)23.21%
EPS NY rev (1m)27.79%
EPS NY rev (3m)51.85%
Revenue NQ rev (1m)2.38%
Revenue NQ rev (3m)3.81%
Revenue NY rev (1m)4.47%
Revenue NY rev (3m)9.44%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 41.02
P/S 16.54
P/FCF 262.31
P/OCF 221.02
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-4.33
EYN/A
EPS(NY)5.51
Fwd EY2.44%
FCF(TTM)0.86
FCFY0.38%
OCF(TTM)1.02
OCFY0.45%
SpS13.66
BVpS-3.09
TBVpS-3.16
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -17.51%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 86.82%
FCFM 6.31%
ROA(3y)-35.96%
ROA(5y)-39.35%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.4%
GM growth 5YN/A
F-Score5
Asset Turnover0.55
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 19.2
Debt/EBITDA N/A
Cap/Depr 47.95%
Cap/Sales 1.18%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.04
Quick Ratio 0.76
Altman-Z 2.24
F-Score5
WACC7.05%
ROIC/WACCN/A
Cap/Depr(3y)22.97%
Cap/Depr(5y)61.4%
Cap/Sales(3y)0.83%
Cap/Sales(5y)68.45%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)42.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.06%
EPS Next Y227.33%
EPS Next 2Y122.09%
EPS Next 3Y85.22%
EPS Next 5Y54.92%
Revenue 1Y (TTM)98.03%
Revenue growth 3Y141.43%
Revenue growth 5Y152.98%
Sales Q2Q%42.31%
Revenue Next Year95.52%
Revenue Next 2Y67.28%
Revenue Next 3Y51.26%
Revenue Next 5Y36.05%
EBIT growth 1Y53.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year442.81%
EBIT Next 3Y144.27%
EBIT Next 5YN/A
FCF growth 1Y114.76%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y117.6%
OCF growth 3YN/A
OCF growth 5YN/A

ASCENDIS PHARMA A/S - ADR / ASND Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for ASCENDIS PHARMA A/S - ADR?

ChartMill assigns a fundamental rating of 4 / 10 to ASND.


What is the valuation status for ASND stock?

ChartMill assigns a valuation rating of 4 / 10 to ASCENDIS PHARMA A/S - ADR (ASND). This can be considered as Fairly Valued.


What is the profitability of ASND stock?

ASCENDIS PHARMA A/S - ADR (ASND) has a profitability rating of 2 / 10.


How financially healthy is ASCENDIS PHARMA A/S - ADR?

The financial health rating of ASCENDIS PHARMA A/S - ADR (ASND) is 3 / 10.